Original Article

Comparison of a Restricted Transfusion Schedule with Erythropoietin Therapy versus a Restricted Transfusion Schedule Alone in Very Low Birth Weight Premature Infants

Authors: Howard J. Birenbaum, MD, Maria A. Pane, MD, Sabah M. Helou, MD, Karen P. Starr, MS, CRNP

Abstract

Objective: Erythropoietin (EPO) is commonly used in very low birth weight neonates to minimize blood transfusions during hospitalization. Data are limited comparing the use of EPO along with a restricted transfusion schedule versus a restricted transfusion schedule alone. We compared the effects of a restricted transfusion schedule with EPO versus a restricted transfusion schedule alone during two consecutive 6-month periods.


Methods: In period I, infants born at <30 weeks gestational age (GA) or <1,500 g birth weight (BW) were treated prophylactically for six weeks with EPO 1,000 U/kg/wk in three divided doses and blood transfusions were given using a restricted transfusion schedule. This was the called the EPO Group. In period II, a restricted transfusion schedule was utilized, but EPO was not administered. This constituted the No EPO Group. No other changes in clinical practice were introduced in either period.


Results: There were 30 neonates in the EPO Group and 20 in the No EPO Group. There were no significant differences in sex, race, mean birth weight (1,074 ± 283 versus 965 ± 330 g), mean gestational age (28.9 ± 2.96 versus 27.8 ± 2.86 wks), 5 minute Apgar score (7.8 ± 1.2 versus 7.6 ± 1.1), or mean hematocrit (48.2% ± 6.05 versus 48.6% ± 6.31) at admission. There were no significant differences in the total number of transfusions between the two periods. In the EPO Group, 8/30 patients received 27 transfusions. Six transfusions violated guidelines based on hematocrit level. EPO was discontinued in three infants secondary to treatment-related neutropenia. There were two deaths unassociated with EPO treatment. Excluding deaths, 6 patients received 16 transfusions. In the No EPO Group, 8/20 patients received 13 transfusions. Two transfusions violated guidelines based on hematocrit. There were three deaths and one patient transfer. Excluding these four patients, 6 infants received 11 transfusions (P≤ 1.) Among survivors, there were no significant differences in mean total length of stay (49.3 ± 22.7 versus 53.2 ± 26.4 d), mean discharge weight (2,144 ± 405 versus 2,358 ± 458 g), or average weight gain/d (20.7 ± 5.44 versus 22.6 ± 6.81 g), between the two groups respectively, nor were there significant differences when all babies were included in the analysis. There was a significant difference in mean hematocrit at discharge, respectively, (38.3% ± 6.84 versus 31.4% ± 6.26; P = 0.003) in survivors.


Conclusions: A restricted transfusion schedule without EPO use was associated with lower mean hematocrit at discharge, but not with an increased frequency of transfusions, nor significant differences in length of stay, discharge weight, or average daily weight gain. A restricted transfusion schedule alone avoided side effects and costs associated with EPO. Indications for transfusion and what constitutes appropriate levels of hemoglobin still require clinical investigation, including long-term clinical outcomes.


Key Points


* Erythropoietin is commonly used in very low birth weight infants to prevent anemia, as is a restricted transfusion schedule without erythropoietin.


* Although hematocrit levels were higher in the erythropoietin-treated group, there was no difference between the groups regarding frequency of transfusions, length of stay, discharge weight, or average daily weight gain.


* A restricted transfusion schedule alone avoided side effects and costs associated with erythropoietin.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cohen A, Manno C. Transfusion practices in infants receiving assisted ventilation. Clin Perinatol1998;25:97–111.
 
2. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108:934–942.
 
3. Maier RF, Obladen M, Seigalla P, et al. The effect of epoietin beta on the need for transfusion in very low birth weight infants. N Engl J Med 1994;330:1173–1178.
 
4. Shannon KM, Keith JF III, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics1995;95:1–8.
 
5. Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatrics 2000;105:1066–1072.
 
6. Franz AR, Pohlandt F. Red blood cell transfusions in very and extremely low birth weight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary? Arch Dis Child Fetal Neonatal Ed 2001;84:96F–100F.
 
7. Ohls RK. Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. J Pediatr 2002;141:3–6.
 
8. Nutritional needs of the preterm infant. In: Pediatric Nutrition Handbook. 5th edition. Elk Grove Village, American Academy of Pediatrics, 2004.
 
9. Ringer SA, Richardson DK, Sacher RA, et al. Variations in transfusion practice in neonatal intensive care. Pediatrics 1998;101:194–200.
 
10. Keyes WG, Donohue MS, Spivak J et al. Assessing the need for transfusion of premature infants and role of hematocrit, clinical signs, and erythropoietin level. Pediatrics 1989;84:412–417.
 
11. Lachance C, Chessex P, Fouron JC, et al. Myocardial, erythropoietic, and metabolic adaptation to anemia of prematurity. J Pediatr 1994;125:278–282.
 
12. Bifano EM, Curran TR. Minimizing donor blood exposure in the neonatal intensive care unit: current trends and future prospects. Clin Perinatol 1995;22:657–669.
 
13. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion transmitted viral infections. N Engl J Med 1996;334:1685–1690.
 
14. Maier RF, Sonntag J, Walka MM, et al. Changing practices of red blood cell transfusion in infants with birth weights less than 1000 g. J Pediatr 2000;136:220–224.
 
15. Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months- corrected age in extremely low birth weight infants treated with early erythropoietin and iron.Pediatrics 2004;114:1287–1291.